Invasion of Influenza A

New Discoveries on Influenza A Viruses (IAVs) Facilitated by high mutation rate of the viral genome and polymerase, IAVs can cause annual epidemics of approximately 500,000 deaths per year and the function interplay between hemagglutinin and neuraminidase glycoprotein characterizes the pathogenic profile of each viral subtype. (Lancet Infect Dis, 2014) IAVs, mimicked as misfolded protein aggregates, carry unanchored ubiquitin chains to exploit host cell’s aggresome processing machinery for efficient IAV entry and capsid dissociation. (Science, 2014) NiPT5, as a potent anti-IAV agent, can suppress the transcription, translation of vRNA and the synthesis of nucleoprotein to impede the early phase of viral replication. (Scientific Reports, 2015) Influenza A Life Cycle (Click to see your products of interest) Eight Product Categories and 550 Products 152 Monoclonal Antibodies 181 Polyclonal Antibodies 10 Antibody Pairs 5 ELISA Kits 48 RNAi 2 FISH Probes 126 Recombinant Proteins 31 Cell Transient Overexpression Lysates Featured Antibodies Seasonal H1N1 Hemagglutinin polyclonal antibody (Cat # PAB16771) Seasonal Hemagglutinin antibody at 2 ug/mL specifically recognizes seasonal influenza virus A H1N1 but not swine-origin influenza virus (S-OIV) A H1N1 Hemagglutinin protein. Influenza A virus Hemagglutinin H5 monoclonal antibody, clone 4H1C10 (Cat # MAB2763) Influenza A virus Hemagglutinin H5 monoclonal antibody, clone 4H1C10 at 2 ug/mL specifically recognizes Avian H5 but not Season H1 Hemagglutinin protein. Seasonal H1N1 Hemagglutinin polyclonal antibody (Cat # PAB16767) Western blot analysis of Hemaggutinin using recombinant seasonal Hemagglutinin (Lanes A & B) and swine-origin Hemagglutinin (Lanes C & D) with Seasonal H1N1 Hemagglutinin polyclonal antibody (Cat # PAB16767) at 2 ug/mL (Lanes A & C) and Swine H1N1 Hemagglutinin polyclonal antibody (Cat # PAB16769) at 2 ug/mL (Lanes B & D). Newly Cited Antibody Influenza A virus nucleoprotein monoclonal antibody, clone InA108 (MAB1272) Belardo, G., et al. investigated the anti-influenza activity by using combination therapy of NTZ with neuraminidase inhibitors against broad range of Influenza A viruses and found positive outcome showing synergistic effect. Abnova’s anti-nucleoprotein monoclonal antibody was used in this study for the detection of viral replication via immunocytochemical staining. (Antimicrob. Agents Chemother., 2014) References Short, K.R., et.al. (2014). Lancet Infect Dis http://dx.doi.org/10.1016/S1473-3099(13)70286-X Banerejee, I., et.al. (2014). Science. DOI: 10.1126/science.1257037 Wong, W.Y., et.al. (2015). Scientific Reports. DOI:10.1038/srep08672 Belardo, B., et.al. (2014). Antimicrob. Agents Chemother. DOI: 10.1128/AAC.03947-14. New Products   96 Phospho-specific Antibodies Abnova’s phospho-specific antibodies, manufactured under rigorous quality control, are designed to target various phosphorylated proteins with high sensitivity and specificity.